{"nctId":"NCT00422084","briefTitle":"Pyronaridine Artesunate (3:1) Versus Coartem® in P Falciparum Malaria Patients","startDateStruct":{"date":"2007-01"},"conditions":["Malaria"],"count":1272,"armGroups":[{"label":"PA group","type":"EXPERIMENTAL","interventionNames":["Drug: Pyronaridine artesunate"]},{"label":"AL group","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Coartem® (artemether lumefantrine)"]}],"interventions":[{"name":"Pyronaridine artesunate","otherNames":["Pyramax"]},{"name":"Coartem® (artemether lumefantrine)","otherNames":["Coartem"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female patients between the age of 3 and 60 years, inclusive.\n* Body weight between 20 kg and 90 kg with no clinical evidence of severe malnutrition.\n* Presence of acute uncomplicated P. falciparum mono-infection confirmed by:\n\n  1. Fever, as defined by axillary/tympanic temperature ≥ 37.5°C or oral/rectal temperature ≥ 38°C, or documented history of fever in the previous 24 hours and,\n  2. Positive microscopy of P. falciparum with parasite density between 1,000 and 100,000 asexual parasite count/μl of blood.\n* Written informed consent, in accordance with local practice, provided by patient and/or parent/guardian/spouse.\n* Ability to swallow oral medication.\n\nExclusion Criteria:\n\n* Patients with signs and symptoms of severe/complicated malaria requiring parenteral treatment according to the World Health Organization Criteria 2000.\n* Mixed Plasmodium infection.\n* Severe vomiting or severe diarrhoea.\n* Known history or evidence of clinically significant disorders.\n* Presence of significant anaemia, as defined by Hb \\<8 g/dL.\n* Presence of febrile conditions caused by diseases other than malaria.\n* Known history of hypersensitivity, allergic or adverse reactions to pyronaridine, lumefantrine or artesunate or other artemisinins.\n* Patients with known disturbances of electrolytes balance, e.g., hypokalaemia or hypomagnesaemia.\n* Use of any other antimalarial agent within 2 weeks prior to start of the study as evidenced by a positive urine test.\n* Female patients of child-bearing potential must be neither pregnant (as demonstrated by a negative pregnancy test) nor lactating, and must be willing to take measures to not become pregnant during the study period.\n* Patients taking any drug which is metabolised by the cytochrome enzyme CYP2D6 (flecainide, metoprol, imipramine, amitriptyline, clomipramine).\n* Received an investigational drug within the past 4 weeks.\n* Known active Hepatitis A IgM (HAV-IgM), Hepatitis B surface antigen. (HBsAg) or Hepatitis C antibody (HCV Ab).\n* Known seropositive HIV antibody.\n* Liver function tests \\[ASAT/ALAT levels\\] \\>2.5 times the upper limit of normal range.\n* Known significant renal impairment as indicated by serum creatinine \\>1.4 mg/dL.","healthyVolunteers":false,"sex":"ALL","minimumAge":"3 Years","maximumAge":"60 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"PCR-Corrected Adequate Clinical and Parasitological Response (ACPR) Rate on Day 28","description":"Percentage of subjects with PCR-corrected adequate clinical and parasitological response (ACPR) on Day 28, defined as absence of parasitaemia on Day 28 without the subject's meeting any of the criteria of early treatment failure, late clinical failure, or late parasitological failure.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"99.5","spread":null},{"groupId":"OG001","value":"99.2","spread":null}]}]}]},{"type":"SECONDARY","title":"PCR-corrected Adequate Clinical and Parasitological Response (ACPR) on Day 14","description":"Percentage of subjects with PCR-corrected adequate clinical and parasitological response (ACPR) on Day 14, defined as absence of parasitaemia on Day 14 without the subject's meeting any of the criteria of early treatment failure, late clinical failure, or late parasitological failure.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"99.9","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]}]},{"type":"SECONDARY","title":"Crude ACPR (Non-PCR Corrected ACPR) on Day 14 and Day 28","description":"Percentage of subjects with adequate clinical and parasitological response (ACPR) on Day 28, without correction by PCR, defined as absence of parasitaemia on Day 28 without the subject's meeting any of the criteria of early treatment failure, late clinical failure, or late parasitological failure.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.9","spread":null},{"groupId":"OG001","value":"97.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Parasite Clearance Time","description":"Parasite clearance time is defined as the time from first dosing to the time of first blood draw with parasite clearance. Parasite clearance is defined as zero presence of asexual parasites for 2 consecutive negative readings taken between 7 and 25 hours apart.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.9","spread":null},{"groupId":"OG001","value":"24.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Fever Clearance Time","description":"Fever clearance time is defined as the time from first dosing to first normal reading of temperature for 2 consecutive normal temperature readings taken between 7 and 25 hours apart","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.9","spread":null},{"groupId":"OG001","value":"8.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With Fever Clearance at Day 1, 2 and 3","description":"Fever clearance time is defined as the time from first dosing to first normal reading of temperature for 2 consecutive normal temperature readings taken between 7 and 25 hours apart.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88.7","spread":null},{"groupId":"OG001","value":"87.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.0","spread":null},{"groupId":"OG001","value":"98.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.5","spread":null},{"groupId":"OG001","value":"99.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Patients With Parasite Clearance at Day 1, 2 and 3","description":"Parasite clearance time is defined as the time from first dosing to the time of first blood draw with parasite clearance. Parasite clearance was defined as zero presence of asexual parasites for 2 consecutive negative readings taken between 7 and 25 hours apart.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"68.1","spread":null},{"groupId":"OG001","value":"52.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.1","spread":null},{"groupId":"OG001","value":"97.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.5","spread":null},{"groupId":"OG001","value":"99.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Adverse Events and Clinically Significant Laboratory Results","description":"Incidence of adverse events and of clinically significant laboratory results, ECG, vital signs or physical examination abnormalities.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"509","spread":null},{"groupId":"OG001","value":"241","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"275","spread":null},{"groupId":"OG001","value":"123","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":849},"commonTop":["Headache","Eosinophilia","Cough","Abdominal pain","Neutropenia"]}}}